<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01833455</url>
  </required_header>
  <id_info>
    <org_study_id>UW-PVC-2012-0510</org_study_id>
    <nct_id>NCT01833455</nct_id>
  </id_info>
  <brief_title>Premature Ventricular Contractions (PVCs) and Blood Pressure Control</brief_title>
  <official_title>The Effects of PVC Suppression on Blood Pressure Control in Patients With Frequent PVCs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if reduction in premature ventricular contraction
      (PVC) burden results in a decrease in blood pressure, sympathetic outflow, plasma
      catecholamines and an improvement in baroreflex gain. Flecainide will be used for PVC
      suppression in a randomized, double-blinded, crossover fashion.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment.
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Arterial Pressure</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean arterial blood pressure was calculated from non-invasive systolic and diastolic arm measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Sympathetic Nerve Activity</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Muscle sympathetic nerve activity was measured as number of bursts of neural activity per 100 heart beats.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Baroreflex Gain</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Arterial baroreflex gain is calculated as slope of the relationship between cardiac cycle length and the corresponding change in systolic blood pressure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Ventricular Premature Complexes</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>PVC Suppression then Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then PVC Suppression</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PVC Suppression using Flecainide</intervention_name>
    <description>Flecainide will be administered to result in a reduction in PVC burden.</description>
    <arm_group_label>PVC Suppression then Placebo</arm_group_label>
    <arm_group_label>Placebo then PVC Suppression</arm_group_label>
    <other_name>Tambocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No PVC Suppression using Placebo</intervention_name>
    <description>Placebo (sugar pills) will be given to result in no alteration in PVC burden.</description>
    <arm_group_label>PVC Suppression then Placebo</arm_group_label>
    <arm_group_label>Placebo then PVC Suppression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Frequent symptomatic premature ventricular contractions (PVCs) (&gt;10% of total QRSs on
             a 24-hour Holter)

          -  Willingness to participate in research

        Exclusion Criteria:

          -  Age &gt; 65 years old

          -  Pacemaker implantation

          -  Implantable cardioverter defibrillator implantation requiring pacing

          -  Sick sinus syndrome

          -  Atrio-ventricular (AV) block

          -  Left ventricular dysfunction defined as left ventricular ejection fraction &lt; 50%

          -  History of myocardial infarction or coronary artery disease

          -  Severe left ventricular hypertrophy (wall thickness &gt; 1.5 cm by echocardiography
             performed within 3 months from enrollment)

          -  Severe liver dysfunction

          -  Creatinine clearance of 35 mL/min/1.73 square meters or less

          -  Pregnancy

          -  Known hypersensitivity to the drug

          -  QRS duration &gt; 120 ms

          -  Recent change in blood pressure medication within 30 days of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed H Hamdan, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 9, 2013</study_first_submitted>
  <study_first_submitted_qc>April 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2013</study_first_posted>
  <results_first_submitted>August 21, 2018</results_first_submitted>
  <results_first_submitted_qc>January 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 22, 2019</results_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PVC Suppression Then Placebo</title>
          <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then PVC Suppression</title>
          <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1st Baseline</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1st Intervention</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 2nd Baseline (Washout)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PVC Suppression Then Placebo</title>
          <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Then PVC Suppression</title>
          <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PVC Burden</title>
          <units>% of heartbeats</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="13"/>
                    <measurement group_id="B2" value="30" spread="13"/>
                    <measurement group_id="B3" value="28" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Arterial Pressure</title>
        <description>Mean arterial blood pressure was calculated from non-invasive systolic and diastolic arm measurements.</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>Mean arterial blood pressure values were not available at all time points for every patient. Data on subjects who completed the study is presented here and may not reflect changes seen in a larger population.</population>
        <group_list>
          <group group_id="O1">
            <title>Change From Base 1 to PVC Suppression</title>
            <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
Change in BP values from baseline to PVC suppression in the group that received flecainide (PVC suppression) first.</description>
          </group>
          <group group_id="O2">
            <title>Change From Base 2 to no PVC Suppression</title>
            <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
Change in BP values from 2nd baseline (washout) to PVC suppression in the group that received flecainide (PVC suppression) first.</description>
          </group>
          <group group_id="O3">
            <title>Change From Base 1 to no PVC Suppression</title>
            <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
Change in BP values from first baseline to no PVC suppression in the group that received placebo (no PVC suppression) first.</description>
          </group>
          <group group_id="O4">
            <title>Change From Base 2 to PVC Suppression</title>
            <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
Change in BP values from 2nd baseline (washout) to PVC suppression in the group that received placebo (no PVC suppression) first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Arterial Pressure</title>
          <description>Mean arterial blood pressure was calculated from non-invasive systolic and diastolic arm measurements.</description>
          <population>Mean arterial blood pressure values were not available at all time points for every patient. Data on subjects who completed the study is presented here and may not reflect changes seen in a larger population.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="2"/>
                    <measurement group_id="O2" value="1" spread="4"/>
                    <measurement group_id="O3" value="3" spread="11"/>
                    <measurement group_id="O4" value="-4" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Muscle Sympathetic Nerve Activity</title>
        <description>Muscle sympathetic nerve activity was measured as number of bursts of neural activity per 100 heart beats.</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>SNA values were not obtained in many of the participants in various groups above due to technical difficulties. Data on subjects who underwent the measurement are presented here and may not reflect changes seen in a larger population.</population>
        <group_list>
          <group group_id="O1">
            <title>Change From Base 1 to PVC Suppression</title>
            <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
Change in SNA values from baseline to PVC suppression in the group that received flecainide (PVC suppression) first.</description>
          </group>
          <group group_id="O2">
            <title>Change From Base 2 to no PVC Suppression</title>
            <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
Change in SNA values from 2nd baseline (washout) to PVC suppression in the group that received flecainide (PVC suppression) first.</description>
          </group>
          <group group_id="O3">
            <title>Change From Base 1 to no PVC Suppression</title>
            <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
Change in SNA values from first baseline to no PVC suppression in the group that received placebo (no PVC suppression) first.</description>
          </group>
          <group group_id="O4">
            <title>Change From Base 2 to PVC Suppression</title>
            <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
Change in SNA values from 2nd baseline (washout) to PVC suppression in the group that received placebo (no PVC suppression) first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Muscle Sympathetic Nerve Activity</title>
          <description>Muscle sympathetic nerve activity was measured as number of bursts of neural activity per 100 heart beats.</description>
          <population>SNA values were not obtained in many of the participants in various groups above due to technical difficulties. Data on subjects who underwent the measurement are presented here and may not reflect changes seen in a larger population.</population>
          <units>bursts / 100 heartbeats</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="-10"/>
                    <measurement group_id="O3" value="-3"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Baroreflex Gain</title>
        <description>Arterial baroreflex gain is calculated as slope of the relationship between cardiac cycle length and the corresponding change in systolic blood pressure.</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>Arterial baroreflex gain values were not available at all time points. In one subject, gain could not be calculated because they were in bigeminy. Data on subjects who completed the study is presented here and may not reflect changes seen in a larger population.</population>
        <group_list>
          <group group_id="O1">
            <title>Change From Base 1 to PVC Suppression</title>
            <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
Change in baroreflex gain values from baseline to PVC suppression in the group that received flecainide (PVC suppression) first.</description>
          </group>
          <group group_id="O2">
            <title>Change From Base 2 to no PVC Suppression</title>
            <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
Change in baroreflex gain values from 2nd baseline (washout) to PVC suppression in the group that received flecainide (PVC suppression) first.</description>
          </group>
          <group group_id="O3">
            <title>Change From Base 1 to no PVC Suppression</title>
            <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
Change in baroreflex gain values from first baseline to no PVC suppression in the group that received placebo (no PVC suppression) first.</description>
          </group>
          <group group_id="O4">
            <title>Change From Base 2 to PVC Suppression</title>
            <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
Change in baroreflex gain values from 2nd baseline (washout) to PVC suppression in the group that received placebo (no PVC suppression) first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baroreflex Gain</title>
          <description>Arterial baroreflex gain is calculated as slope of the relationship between cardiac cycle length and the corresponding change in systolic blood pressure.</description>
          <population>Arterial baroreflex gain values were not available at all time points. In one subject, gain could not be calculated because they were in bigeminy. Data on subjects who completed the study is presented here and may not reflect changes seen in a larger population.</population>
          <units>ms/mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1"/>
                    <measurement group_id="O2" value="6" spread="2"/>
                    <measurement group_id="O3" value="8" spread="5"/>
                    <measurement group_id="O4" value="15" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Base 1 to PVC Suppression</title>
          <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
Adverse events during baseline to PVC suppression in the group that received flecainide (PVC suppression) first.</description>
        </group>
        <group group_id="E2">
          <title>Base 2 to no PVC Suppression</title>
          <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
Adverse events during 2nd baseline (washout) to PVC suppression in the group that received flecainide (PVC suppression) first.</description>
        </group>
        <group group_id="E3">
          <title>Base 1 to no PVC Suppression</title>
          <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
Adverse events during first baseline to no PVC suppression in the group that received placebo (no PVC suppression) first.</description>
        </group>
        <group group_id="E4">
          <title>Base 2 to PVC Suppression</title>
          <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
No PVC Suppression using Placebo: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
PVC Suppression using Flecainide: Flecainide will be administered to result in a reduction in PVC burden.
Adverse events during 2nd baseline (washout) to PVC suppression in the group that received placebo (no PVC suppression) first.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated prematurely due to a loss of staff available to make the technical measurements involved. The small number of data points available lead us to conclude the data is uninterpretable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Stephen Wasmund, PhD</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>801-587-3740</phone>
      <email>stephen.wasmund@carma.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

